<DOC>
	<DOC>NCT01582243</DOC>
	<brief_summary>This study will assess the efficacy of vildagliptin plus metformin (SPC) treatment in type 2 diabetes mellitus patients uncontrolled by metformin monotherapy after 24 weeks treatment</brief_summary>
	<brief_title>Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria 1. Outpatients who were 20 years of age and older with diagnosis of T2DM. 2. Patients who had been treated with stable dose of metformin (≥1000 mg/day) monotherapy at least 4 weeks prior to Visit 1 and had failed to achieve the glucose control goal. The glucose control goal was defined as HbA1c ≤ 6.5%. 3. Male or female with childbearing potential agreed to use an effective method of contraception approved by the investigator during the study. 4. Understood the nature of the study, and had signed informed consent form. Exclusion criteria 1. Patients with contraindications mentioned in the Summary of Product Characteristics for vildagliptin or metformin. 2. Patients with renal dysfunction defined as creatinine clearance &lt; 60 ml/min at Visit 1. 3. Patients with history of hepatic impairment, including but not limited to those with pretreatment AST or ALT &gt; 3 ULN at Visit 1. 4. Female patients who needed to lactate during the study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Mellitus, type 2</keyword>
	<keyword>vildagliptin</keyword>
</DOC>